Anke Muth
3 Papers
Anke Muth is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
Alexandros Papachristofilou,Madeleine M. Hipp,Ute Klinkhardt,Martin Früh,Martin Sebastian,Christian Weiss,Miklos Pless,Richard Cathomas,Wolfgang Hilbe,Georg Pall,Thomas Wehler,Jürgen Alt,Helge Bischoff,Michael Geißler,Frank Griesinger,Karl-Josef Kallen,Mariola Fotin-Mleczek,Andreas Schröder,Birgit Scheel,Anke Muth,Tobias Seibel,Claudia Stosnach,Fatma Doener,Henoch S. Hong,Sven D. Koch,Ulrike Gnad-Vogt,Alfred Zippelius +26 more
TL;DR: In comparison to baseline, immunomonitoring revealed increased BI1361849 antigen-specific immune responses in the majority of patients (84%), whereby antigen- specific antibody levels were increased in 80% and functional T cells in 40% of patients, and involvement of multiple antigen specificities was evident in 52% of Patients.
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
Martin Sebastian,Martin Sebastian,Andreas Schröder,Birgit Scheel,Henoch S. Hong,Anke Muth,Lotta von Boehmer,Lotta von Boehmer,Alfred Zippelius,Frank Mayer,Martin Reck,Djordje Atanackovic,Michael Thomas,Folker Schneller,Jan Stöhlmacher,Helga Bernhard,Andreas Gröschel,Thomas Lander,Jochen Probst,Tanja Strack,Volker Wiegand,Ulrike Gnad-Vogt,Karl-Josef Kallen,Ingmar Hoerr,Florian Von Der Muelbe,Mariola Fotin-Mleczek,Alexander Knuth,Alexander Knuth,Sven D. Koch +28 more
TL;DR: CV9201 was well-tolerated and immune responses could be detected after treatment supporting further clinical investigation, and antigen-specific immune responses against ≥ 1 antigen were detected in 63% of evaluable patients after treatment.
156
A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors.
Thomas Eigentler,Franz G Bauernfeind,Jürgen C. Becker,Peter Brossart,Michael Fluck,Lucie Heinzerling,Jürgen Krauss,Peter Mohr,Sebastian Ochsenreither,Jutta Sylvina Schreiber,Patrick Terheyden,Benjamin Weide,Carsten Weishaupt,Fatma Funkner,Anke Muth,Sarah-Katharina Kays,Claudia Stosnach,Angelika Daehling,Gianluca Quintini,Senta Ulrike Gnad-Vogt +19 more
TL;DR: CV8102 is a non-Coding, non-capped RNA that activates the innate (via TLR7/8, RIG-I) and adaptive immunity dose-dependently and is injected intratumorally as a single agent to activate immunity.
10